Patents/Assignees

Kdac Therapeutics, Inc.

1 patent in portfolio

US12128018utility2024
Combination of a Selective Histone Deacetylase 3 (HDAC3) Inhibitor and an Immunotherapy Agent for the Treatment of Cancer
0 cites